GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Debt-to-Revenue

Mind Medicine (Mind Medicine) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mind Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Mind Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.19 Mil. Mind Medicine's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.


Mind Medicine Debt-to-Revenue Historical Data

The historical data trend for Mind Medicine's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Debt-to-Revenue Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A N/A N/A

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Mind Medicine's Debt-to-Revenue

For the Biotechnology subindustry, Mind Medicine's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Debt-to-Revenue falls into.



Mind Medicine Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mind Medicine's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 14.129) / N/A
=N/A

Mind Medicine's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Mind Medicine Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (Mind Medicine) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.